The Minneapolis-based medtech startup’s lifetime financing now tops $30 million.
The new capital will allow the Brooklyn Park heart therapies maker to hire up to ten new workers, expand into a larger headquarters, and fund new rounds of further testing of its AltaValve device.
The hearing aid maker’s new Livio AI product, the “world’s first multi-use hearing aid,” features improved sound elements and 3D motion sensors for health tracking.
The fund has invested $500K so far; Ambient Clinical Analytics is the latest recipient.
OmniTier says its new tech platform has big implications for the spread of personalized medicine.
Capital from Urotronic's biggest funding round yet will help advance its work on a drug-coated medical balloon meant to provide a safer treatment for urethra blockages.
The platform allows health researchers to bring zebrafish embryos to life after freezing.
A new 13-member research team will analyze the relationship between gut bacteria and colon cancer.
Sansoro will use the new capital – contributed by existing investors and lead investor of the round LRVHealth – to grow efforts to improve data integration for electronic health records.
The Minneapolis-based startup will use the National Institute of Mental Health grant toward further development of its wearable device that treats impulsive behaviors.
Nothing has been confirmed yet, but a report from Axios indicates the Minnesota-based insurance giant will buy Washington-based pharmacy company Genoa Health.
Company also inks deal to co-develop laser device to treat arterial disease.
The Eden Prairie-based company specializing in brain issue detection is in the midst of a hefty fundraising campaign. The first investment was obtained early this month, with more than $9 million more to go toward its target.
Miromatrix, Superior Organoid, and MNPHARM each landed $100,000 regenerative medicine awards.
The company is working towards clinical trials for its implantable kidney and liver products.
A collaboration between Mayo and Exact Sciences is yielding accurate blood DNA tests for treatable cases.
Noaber Foundation led a $1.5 million venture round for the digital health platform.
The move from California to Minnesota comes as the chronic lower back pain device maker has wrapped a $58 million fundraising round.
The deal continues a string of transactions by Bio-Techne over the last five years and marks its foray into the diagnostics area of cancer medicine.
The possible deal sent Boston Scientific’s shares up about 7.5 percent and Stryker’s down by more than 5 percent.
Magenta Therapeutics looks to expand the amount of stem cells for marrow transplants.
The new printer has been proven capable of printing out skin cells to repair wounds in tests on mice.
Cytox Ltd. will use bio-samples from Mayo to develop an algorithm predicting genetic vulnerability.
Partnering company MRI Interventions says the next step will be filing a 510(k), which will come in the third quarter.
The institute will focus on treatments for “cellular senescence” to slow the aging process.
It will play a key role in the U.S. “All of Us” effort to advance individualized medicine.
IPO documents reveal potential of clinic’s collaboration with Evelo Biosciences.
Powered by the Mayo Clinic’s AI, research claims it can read blood potassium with a touch.
Shares of the Maple Grove sleep apnea device maker were up more than 50 percent on its opening day.
The money will go toward advancing the company’s efforts to treat acute decompensated heart failure.